Your session is about to expire
← Back to Search
Other
Inositol for Bipolar Disorder
Phase 1 & 2
Waitlist Available
Led By Ronald Glick, MD
Research Sponsored by Ronald M. Glick, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 1 & week 10-12
Awards & highlights
No Placebo-Only Group
Summary
This trial tests inositol, a sugar-like supplement, on young individuals with bipolar disorder and anxiety. The goal is to see if it can safely improve mood and reduce anxiety by helping brain chemicals work better. Inositol has been studied for its potential benefits in various psychiatric disorders, including depression, anxiety, and bipolar disorder.
Eligible Conditions
- Bipolar Disorder
- Generalized Anxiety Disorder
- Anxiety Disorders
- Anxiety
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 1 & week 10-12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 1 & week 10-12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To measure the safety and tolerability of myo-inositol, a change from baseline on the Physical Symptom Checklist (Side Effect Rating Scale) will be measured.
To measure the safety of myo-inositol, a fingerstick blood test will be done to measure glucose levels at the first and final study visits.
To measure the safety of myo-inositol, anxiety and mood symptoms will be measured using Clinical Global Impression Severity (CGI-S).
+5 moreSecondary study objectives
Anxiety
To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on Clinical Global Impression Improvement (CGI-I) will be evaluated.
To measure the effectiveness of myo-inositol for anxiety symptoms, a change from baseline on Clinical Global Impression Severity (CGI-S) will be evaluated.
+4 moreSide effects data
From 2019 Phase 4 trial • 69 Patients • NCT0139648614%
Nausea/Vomit/Diarrhea
5%
Increased Appetite
5%
Cold/Infection/Allergy
5%
Insomnia
5%
Pulmonary
5%
Earache
5%
Thirsty
5%
Neurological
5%
Headache
5%
Tics
5%
Musculoskeletal
5%
Autonomic
5%
Dizzy/Lightheaded
5%
Agitated with Homicidal Statements
100%
80%
60%
40%
20%
0%
Study treatment Arm
Omega-3/Placebo
Omega-3/Inositol
Placebo/Inositol
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: InositolExperimental Treatment1 Intervention
Subjects will receive inositol
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Inositol
2012
Completed Phase 4
~140
Find a Location
Who is running the clinical trial?
Ronald M. Glick, MDLead Sponsor
Jarrow Formulas IncIndustry Sponsor
5 Previous Clinical Trials
648 Total Patients Enrolled
The Fine FoundationUNKNOWN
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You currently have thoughts of hurting yourself or others, or you have a mental illness that causes you to lose touch with reality.
Research Study Groups:
This trial has the following groups:- Group 1: Inositol
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger